Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 131 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2017  |  Volume : 21  |  Issue : 5  |  Page : 762-764

Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool

1 Director, Bharti Hospital and BRIDE, Karnal, Haryana, India
2 Director, Chellaram Diabetes Institute, Pune, Maharashtra, India
3 Excel Center(Initiative of Excelcare Hospitals Pvt. Ltd.), Guwahati, Assam, India
4 Department of Medical Affairs, Boehringer Ingelheim, Mumbai, Maharashtra, India

Correspondence Address:
Sanjay Kalra
Bharti Hospital and BRIDE, Karnal-132001, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijem.IJEM_184_17

Rights and Permissions

Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded314    
    Comments [Add]    
    Cited by others 2    

Recommend this journal